Incidence and characteristics of acute intraocular inflammation after intravitreal injection of bevacizumab: A retrospective cohort study

Canadian Journal of Ophthalmology

Volumn 45, Issue 3, 2010, Pages 239-242

  Johnson, Davin ^a   Hollands, Hussein ^a   Hollands, Simon ^a   Sharma, Sanjay ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Bevacizumab; Macular degeneration; Uveitis endophthalmitis

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; PREDNISOLONE ACETATE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ANTERIOR EYE CHAMBER DISEASE; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DISEASE ASSOCIATION; DISEASE SEVERITY; EYE INFLAMMATION; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; HUMAN TISSUE; HYPOPYON; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYOPIA; RETINA MACULA AGE RELATED DEGENERATION; RETINA VEIN OCCLUSION; RETROSPECTIVE STUDY; SURGEON; TERTIARY HEALTH CARE; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS DISEASE; ACUTE DISEASE; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; ENDOPHTHALMITIS; INCIDENCE; INJECTION; MIDDLE AGED; RISK ASSESSMENT; UVEITIS; VERY ELDERLY; VITREOUS BODY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ENDOPHTHALMITIS; FEMALE; HUMANS; INCIDENCE; INJECTIONS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; UVEITIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 77953300103     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/i10-013     Document Type: Article

References (12)

1. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-87
2. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349 (Pubitemid 44702055)
3. Ladas ID, Karagiannis DA, Rouvas AA, Kotsolis AI, Liotsou A, Vergados I. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina 2009;29:313-318
4. Shima C, Sakaguchi H, Gomi F, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 2008;86:372-376
5. Wickremasinghe SS, Michalova K, Gilhotra J, et al. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 2008;115:1911-1915
6. Georgopoulos M, Polak K, Prager F, Prunte C, Schmidt-Erfurth U. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol 2009;93:457-462
7. Genentech. Reports of Intraocular Inflammatory Reactions After Intravitreal Injection with AVASTIN; 2008.
8. Fielden M, Nelson B,Williams G, Ells A, Anand J, Kherani A. Acute intraocular inflammation following intravitreal injection of bevacizumab - a cluster of cases. Paper presented at the Canadian Ophthalmology Society Annual Conference and Exhibition, Toronto, 2009.
9. Hall R, Lodha N, Mitchell P, Williams G, Kherani A. Incidence of ocular complications following intravitreal bevacizumab (Avastin) injections. Paper presented at the Canadian Ophthalmology Society Annual Conference and Exhibition, Toronto, 2009.
10. Holland S, Ma P, Maberley D, et al. Outbreak of acute intraocular inflammation after bevacizumab intravitreal injection: an epidemiological investigation. Paper presented at the Canadian Ophthalmology Society Annual Conference and Exhibition, Toronto, 2009.
11. Wilson E. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 1927;22:209-212
12. Canadian Ophthalmology Society. TASS/ID Task Force Hotline. 2009. Available at: www.eyesite.ca/english/press/TASS-e.pdf.